Together, we can make a meaningful impact in healthcare.
Therapeutic areas to explore with Incannex include Dermatology, Gastrointestinal, Inflammation, Neurodegenerative Diseases, Neuropsychiatric Disorders, and Ophthalmology. For more information on our lead programs and other clinical-stage assets, please contact our business development team.
Contact Us
Our Programs
-
|IHL-42X
IHL-42X is an oral fixed-dose combination therapy of acetazolamide and dronabinol currently in clinical studies for the treatment of obstructive sleep apnea (OSA).
-
|IHL-675A
IHL-675A is an oral fixed-dose combination of a synthetic cannabidiol and hydroxychloroquine sulfate (HCQ) that is currently in Phase 2 development for the treatment of rheumatoid arthritis (RA).
-
|PSX-001
PSX-001 is an oral synthetic psilocybin currently being studied in combination with psychological support as a treatment for adults with generalized anxiety disorder (GAD).